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Abstract 
Objectives. Fluoride mouthrinses provide advantages for fluoride delivery by maintaining 
elevated intra-oral fluoride concentrations following fluoride dentifrice use. This in situ caries 
study investigated potential anti-caries efficacy of a 220 ppm fluoride mouthrinse  
Methods. This was an analyst-blinded, four-treatment, randomised, crossover study using 
partially demineralised, gauze-wrapped, human enamel samples mounted in a mandibular 
partial denture. Participants brushed twice daily for 14 days with either a 1150 ppm fluoride 
or fluoride-free placebo dentifrice and either rinsed once daily with the 220 ppm fluoride 
mouthrinse or not. Following each treatment period, percent surface microhardness recovery 
(%SMHR) and enamel fluoride uptake (EFU) were assessed. 
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Results. Fifty three participants completed the study. Compared with the placebo 
dentifrice/no rinse treatment, the fluoride-containing regimens demonstrated greater enamel 
remineralisation (%SMHR) and fluoridation (EFU): fluoride dentifrice/fluoride rinse (%SMHR 
difference: 21.55 [95% CI: 15.78,27.32]; EFU difference 8.35 [7.21,9.29]); fluoride 
dentifrice/no rinse: 19.48 [13.81,25.15]; 6.47 [5.35,7.60]; placebo dentifrice/fluoride rinse: 
16.76 [11.06,22.45]; 5.87 [4.72,7.00]) (all P < .0001). There were no significant differences in 
%SMHR between fluoride regimens. The fluoride dentifrice/fluoride rinse regimen was 
associated with higher EFU than the fluoride dentifrice/no rinse (1.88 [0.75,3.01], P = .0013) 
and placebo dentifrice/fluoride rinse regimens (2.48 [1.34,3.62], P < .0001). Treatments were 
generally well-tolerated. 
Conclusions. The in situ caries model demonstrated that the fluoride mouthrinse is effective 
in promoting enamel caries lesion remineralisation and fluoridation whether used following a 
fluoride or non-fluoride dentifrice. Additive (potential) anti-caries benefits of a fluoride rinse 
after a fluoride dentifrice were confined to enhancements in lesion fluoridation (EFU). 
Clinical Significance. In conjunction with a fluoride dentifrice, fluoride mouthrinses enhance 
enamel fluoridation, which may be useful in caries prevention. 
 
Key Words: caries; dentifrice; fluoride; in situ model; mouthrinse; remineralisation 
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1. Introduction 
Brushing with fluoride-containing dentifrice products has been shown in numerous clinical 
trials to be effective in reducing dental caries [1,2]. Fluoride has two relevant mechanisms of 
action: inhibition of acid-induced demineralisation (that could lead to dental caries), which is 
beneficial as fluoridated enamel is more acid-resistant than native enamel, and 
enhancement of remineralisation of partially demineralised enamel during the early stages of 
caries in the presence of calcium and phosphate ions from saliva [3,4]. 
For individuals at high risk of developing dental caries, fluoride mouthrinses are 
recommended in addition to fluoride dentifrices [5,6]. Cochrane Collaboration systematic 
reviews of fluoride mouthrinses have reported that the supervised use of fluoride mouthrinse 
by children is associated with a clear reduction in caries increment based on a meta-analysis 
of 35 trials [7], and that use of fluoride mouthrinse can reduce dental caries irrespective of 
exposure to fluoridated water [8]. A systematic review of fluoride mouthrinses in populations 
of various ages found a caries-preventive effect in the permanent teeth of schoolchildren 
and adolescents with no additional fluoride exposure [9]. While the authors found a caries-
preventive effect of fluoride mouthrinses on root caries in older adults, they questioned the 
additional benefit in children using fluoride dentifrice daily. Although a number of clinical 
studies have explored the adjunctive benefit of fluoride mouthrinses, few studies have 
explored the role of fluoride mouthrinses in the fundamental aspects of the caries process.    
The use of in situ surrogate caries models as an approach to evaluate the anti-caries 
efficacy of fluoride dentifrices and other fluoride-containing dental products, such as 
mouthrinses, is generally well-recognised and accepted [10]. In particular, modifications of 
the Koulourides intra-oral model [11] have led to the development of an in situ caries model 
[10] with sufficient sensitivity and reproducibility to respond in a dose-dependent manner to 
meet the requirements for model validation [12]. For the current study, the potential anti-
caries efficacy of dentifrices and mouthrinses in remineralising previously demineralised 
enamel specimens was investigated using the surface microhardness (SMH) test to 
accurately determine the changes occurring at the enamel surface during the early stages of 
the caries process [10]. The SMH test has been used widely to evaluate enamel 
remineralisation in studies involving in situ caries models and has been shown to have 
greater sensitivity in comparison to other techniques such as cross-sectional microhardness 
and transverse microradiography to evaluate enamel remineralisation of shallow caries-like 
lesions. [10,11,13–16].  
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The primary objective of this study was to evaluate and compare the potential anti-caries 
efficacy of a regimen consisting of a fluoride mouthrinse once daily plus brushing with a 
fluoride-free placebo dentifrice twice daily versus only twice daily brushing with the placebo 
dentifrice, to remineralise previously demineralised enamel specimens, as measured by 
percent SMH recovery (%SMHR). Secondary objectives were to compare the potential anti-
caries efficacy of other treatment regimens comprising the fluoride mouthrinse plus a fluoride 
dentifrice and the fluoride dentifrice alone. Further secondary objectives were to evaluate 
and compare treatments with respect to enamel fluoride uptake (EFU), and pre- and post-
treatment changes in salivary fluoride concentrations, and to explore the relationship 
between EFU and salivary fluoride concentrations and the results of enamel remineralisation 
based on %SMHR. 
 
2. Materials and Methods 
This was a single-centre, analyst-blind, four-treatment, crossover, randomised in situ model 
study performed at the Oral Health Research Institute, Indiana University School of 
Dentistry, USA. It was approved by the Indiana University Institutional Review Board (# 
1503890832) and was conducted in accordance with the Declaration of Helsinki. This study 
is registered at clinicaltrials.gov; study number NCT02399163. 
2.1. Participants 
Healthy participants aged 18–85 years were recruited from the Indianapolis area (where 
community water contains approximately 1 µg/mL fluoride). All participants provided written 
informed consent prior to screening. Participants were required to have a removable 
mandibular partial denture suitable to retain two enamel specimens and be willing and 
capable of wearing their denture 24 hours/day during the experimental periods. They were 
required to be in good general and dental health with an unstimulated and stimulated saliva 
flow rate of at least 0.2 mL/minute and at most 0.8 mL/minute, respectively, and not to have 
had a professional fluoride treatment within 14 days before the first treatment visit. 
Participants could not have any active caries or periodontal disease that in the opinion of the 
investigator could compromise the study. Participants were excluded if they were pregnant, 
intending to become pregnant, or were breastfeeding; had a known or suspected intolerance 
to the study materials; were taking antibiotics or had taken antibiotics in the two weeks 
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before the screening visit; or if they were taking or had taken a bisphosphonate drug for 
treatment of osteoporosis. 
2.2. Experimental design and study procedures 
At the screening visit, participants underwent an oral soft tissue (OST) and oral hard tissue 
(OHT) examination and their salivary flow rate was measured. An OST examination was 
also performed during the visit before and after each treatment period; an additional OHT 
examination was performed at the first prophylaxis visit before the first treatment period. 
Each participant undertook treatments in a crossover design in four successive 2-week 
treatment periods. Between each treatment period, participants used their usual dentifrice 
for at least 4 days, and then reported to the study site 2–3 days before the start of each of 
the four treatment periods, where they had an OST examination and underwent dental 
cleaning using a fluoride-free prophylaxis dentifrice. The fluoride-free dentifrice formulation 
used during the study period and a study toothbrush (Aquafresh® Toothbrush 3-Way head; 
GSK Consumer Health, Weybridge, Surrey, UK) were dispensed to participants for use 
before starting the next treatment period.  
At the start of the first treatment period, eligibility to continue in the study was assessed and 
then participants were randomised to the sequence in which they received the four study-
treatment regimens. The order in which each participant received the treatment regimens 
was determined by a randomisation schedule provided by the Biostatistics Department of 
GSK Consumer Healthcare. A Latin square was use to ensure uniform design (Williams 
square design). Randomisation numbers were assigned in ascending numerical order as 
each participant was determined to be fully eligible for the study. The following dentifrices 
and mouthrinse were used in the study: 
 Fluoride dentifrice: Aquafresh® Extreme Clean® Pure Breath Action fluoride 
dentifrice containing 1150 ppm fluoride as sodium fluoride (GSK Consumer 
Healthcare, Weybridge, Surrey, UK; USA marketed product); 
 Fluoride mouthrinse: containing 220 ppm of fluoride as sodium fluoride (non-
marketed formulation); 
 Control placebo dentifrice: non-fluoride dentifrice (non-marketed formulation). 
In each treatment period, participants were assigned to one of the following treatment 
regimens: fluoride dentifrice/fluoride rinse; fluoride dentifrice/no rinse; placebo 
dentifrice/fluoride rinse; placebo dentifrice/no rinse. By the end of the study, all participants 
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experienced all four treatment regimens. Supplied dentifrices were overwrapped to blind as 
far as possible participants to dentifrice allocation; however, study group could not be fully 
blinded as participants would know whether or not they were in a fluoride rinse group. The 
site laboratory analyst, study statistician, data management staff and other employees of the 
Sponsor who could have influenced study outcomes were blinded to treatment allocation. 
Study product(s) were dispensed to the participants, who completed the initial 
brushing/rinsing under supervision at the study site then used the study products at home for 
the rest of the 2-week treatment period. Participants were provided with a diary card to 
record brushing and/or rinsing times, any adverse events (AEs), and concomitant 
medications until their next visit. The diary cards were used to assess compliance to study 
procedures.  
At the start of each treatment period, two partially demineralised enamel specimens were 
mounted in the participant’s mandibular partial denture. During the 2-week treatment 
periods, participants brushed twice daily (after breakfast and just before bedtime) and wore 
their mandibular partial denture continuously for 24 hours, except as specified during the 
brushing procedure and for cleaning. At each brushing, participants removed their partial 
denture and cleaned their natural teeth with water and the study toothbrush. They cleaned 
the denture outside of the mouth with the study toothbrush and water only, taking care not to 
brush the enamel specimens, and then reinserted the denture. The participants then 
brushed their natural and denture teeth for 1 timed minute using a full ribbon of assigned test 
dentifrice on the study toothbrush, again taking care not to brush the enamel specimens. 
Participants then rinsed with 10 mL of tap water for 5 seconds, and (where allocated) rinsed 
with mouthrinse for 1 minute immediately after the night-time brushing, with their denture in 
place. 
Between each treatment period, participants used their usual dentifrice for at least 4 days, 
and then switched to the wash-out fluoride-free dentifrice for 2–3 days before starting the 
next treatment period. This process was repeated until all participants had used all four test 
treatment regimens, as specified in the randomisation schedule. 
Two unstimulated saliva samples for fluoride concentration assessment were collected 
during the visit at the beginning of each study period; one before supervised brushing/rinsing 
and one immediately after. At the end of each 2-week treatment period, participants returned 
to the study site where an OST examination was performed and an unstimulated saliva 
sample for fluoride assessment was collected. The enamel specimens were removed from 
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the mandibular partial denture and analysed. At the participant’s final study visit an OHT 
exam was also conducted. 
2.3. Lifestyle restrictions 
Participants were instructed not to use any fluoride dentifrices or other fluoride-containing 
oral-hygiene products for a minimum of 2 days before the start of each treatment and to 
refrain from rinsing with water for 30 minutes after use of the mouthrinse. During the 
treatment and wash-out periods, participants were instructed not to use other oral hygiene 
products with the exception of interproximal cleaners, e.g., dental floss, if this was their 
normal practice. Participants could remove their partial denture for short periods to rinse 
their mouth with tap water after meals and snacks. No denture adhesive could be used in 
the mandibular partial denture; a zinc-free adhesive could be used for an upper denture if 
needed. Participants were asked to refrain from eating canned sardines during the course of 
the study, as these may have high fluoride levels. 
2.4. Preparation of enamel specimens and in situ devices 
2.4.1. Enamel specimens 
Specimens obtained from human permanent teeth were prepared as previously described 
[17]. Briefly, enamel specimens (4 mm × 4 mm) were cut, ground and polished to provide a 
minimum surface of 3 mm × 3 mm in the centre of the enamel surface for testing of SMH 
[18]. Five baseline indentations, 100 µm apart, were placed in the centre of each specimen 
using a Knoop diamond under a 50 g load. Only those specimens with a mean indentation 
length of 43 ±3 µm were used. For assessment of SMHR, the specimens were first partially 
demineralised using a modification of the method described by White [19] by immersion in 
an acid buffer (0.05 mol/L lactate), 50% saturated with respect to hydroxyapatite, containing 
0.2% (w/v) polyacrylic acid (Carbopol® C907; BF Goodrich, Cleveland, OH, USA), pH 5.0, for 
24 hours at 37°C. Following demineralisation, the SMH was again measured by placing a 
further five indentations 100 µm to the left of the sound enamel indentations on each 
specimen. Specimens with a mean indentation length of 120 ±20 µm were used in the study. 
Before insertion into the participant’s partial dentures, all enamel specimens were sterilized 
with ethylene oxide gas. 
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2.4.2. Intra-oral appliance 
The participants’ mandibular partial dentures were modified for study use by creating a 
hollow in the buccal flange area to accommodate the enamel specimens. Two partially 
demineralised enamel specimens were placed in the buccal flange area and covered with 
polyester knit fabric (Item #R01628, Impra, Tempe, AZ, USA) to encourage plaque formation 
[11,20]. The specimens were mounted such that the enamel surface of the specimen was 
flush with the surface of the buccal flange of the participant's partial denture and luted in 
place using a light-cured dental composite (Triad VLC material, Dentsply Int., York, PA, 
USA). On completion of the study, the participant’s partial denture was permanently repaired 
with acrylic. 
2.5. Assessments 
2.5.1. Assessment of enamel remineralisation 
Changes in the mineral status of the enamel specimens were assessed by measuring SMH 
using a Wilson 2100 Hardness Tester, as previously described [21]. After the in situ phase, 
five indentations spaced 100 μm apart were placed 100 µm to the right of the sound enamel 
indentations and the length of each indentation was measured.  
The extent of remineralisation was calculated based on the method of Gelhard and 
colleagues [13]: 
%SMHR = [(D1−R)/(D1−B1)] × 100 
Where B = indentation length (μm) of sound enamel specimen at baseline; D1 = indentation 
length (μm) after in vitro demineralisation; and R = indentation length (μm) after intra-oral 
exposure. 
2.5.2. Assessment of enamel fluoride bioavailability 
Following completion of the SMH procedures, enamel specimens were analysed for EFU 
using the microdrill enamel biopsy technique as described by Sakkab and colleagues [22]. 
Four 100 μm cores were taken per specimen; core diameters were determined using a 
calibrated microscope interfaced with an image analysis system. The amount of fluoride 
uptake by enamel was calculated based on the amount of fluoride in the pooled powder 
sample divided by the total cross-sectional area of the enamel cores, and expressed as 
μg F/cm2. 
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2.5.3. Salivary fluoride concentration 
Salivary fluoride concentration was analysed using the Martinez-Mier and colleagues [23] 
modification of the hexamethyldisiloxane microdiffusion method of Taves [24],  and 
expressed as µg F/mL. 
2.6. Safety 
The safety population included all randomised participants who received study treatment(s). 
The safety and tolerability of the study treatment regimens were assessed with respect to 
treatment-emergent AEs recorded from the start of the prophylaxis procedure until 5 days 
following last administration of the investigational product. AEs were graded as mild, 
moderate or serious according to the clinical judgment of the investigator. Any AEs occurring 
during the washout period between treatments were assigned to the last experimental 
treatment administered. 
2.7. Data analysis 
2.7.1 Sample size determination 
A sufficient number of participants were screened so that a maximum of 62 participants 
could be randomised to participate in the study to ensure that approximately 50 participants 
were evaluable for the efficacy analysis. This sample size was calculated to have 90% 
power to detect a mean difference of 7.91% in %SMHR between treatment groups, based 
on an estimated within-participant standard deviation of 11.96% (determined from previous 
unpublished results), and with a significance level of 0.05 using a two-sided paired t-test. 
2.7.2 Efficacy analyses 
The intent-to-treat (ITT) population was defined as all participants who were randomised, 
received at least one dose of study product and had at least one post-baseline efficacy 
assessment. Efficacy analyses were conducted on the per-protocol (PP) population, defined 
as participants in the ITT population who had no protocol violations deemed to affect efficacy 
during the study. All outcome variables were analysed under a null hypothesis of no 
difference between study treatments against an alternate hypothesis of a difference between 
study treatments. All significance testing was conducted at the two-sided 5% significance 
level with no adjustments for multiple testing.  
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The primary efficacy variable was the %SMHR in the PP population. The mean %SMHR 
was computed by averaging the two within-participant specimen-level results for each 
treatment. Percent SMHR, EFU and salivary fluoride concentration were evaluated using an 
analysis of variance (ANOVA) model with %SMHR as the dependent variable, fixed effects 
of treatment and study period, and a random effect of participant. The assumptions 
underlying the ANOVA model for each assessment were examined and the homogeneity of 
variance assumption was violated in that the variability in the placebo group was much less 
than in the other groups. As a consequence, Wilcoxon signed-rank tests were also 
performed to investigate the effect of this violation on between-treatment group inferences. 
The correlations between mean %SMHR, EFU, and salivary fluoride differences were 
examined by treatment. Pearson’s correlation coefficients (95% confidence intervals and P-
values) were calculated between each pair of endpoints. 
All analyses were performed using SAS 9.2 with Proc Mixed for ANCOVA (SAS Institute 
Inc., Cary, NC, USA). 
 
3. Results 
3.1. Participants 
A total of 80 participants were screened and 62 were randomised to treatment (Figure 1). 
The first participant was enrolled on April 20 2015 and the last participant completed the 
study on August 5 2015. All randomised participants were included in the safety population, 
which had a mean age of 64.1 years (standard deviation 10.45 years, range 35–83 years); 
35 (56.5%) were female and the participants were predominantly white (n=30; 48.4%) or 
black/African American (n=30; 48.4%). 
3.2. Efficacy 
Endpoints were analysed for the PP population as less than 5% of participants (n=2) were 
excluded from this population (Figure 1). These participants were excluded due to non-
compliance with the rinsing period or the washout period or their treatment period being 
outside the acceptable range. A further 10 participants had a protocol violation that led to 
exclusion of data from at least one, but not all analysis. Final participant numbers are shown 
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in Figure 2. Wilcoxon signed-rank test p-values are given for comparison between 
treatments. 
3.2.1. %SMH recovery 
Baseline values did not vary significantly between the groups. All three active-treatment 
regimens (fluoride dentifrice/fluoride rinse, fluoride dentifrice/no rinse, placebo 
dentifrice/fluoride rinse) were associated with statistically significantly greater %SMHR than 
the placebo dentifrice/no rinse treatment (Figure 2a; Table 1; all comparisons P < .0001). 
There were no statistically significant differences in %SMHR between the three active 
(fluoride) treatment groups. Analysis from the ANOVA model provided similar results 
(Table 1). 
3.2.2. Enamel fluoride uptake 
In all three active treatment groups, EFU was statistically significantly higher than in the 
placebo/no rinse group (Figure 2b, Table 2; P < .0001 for all comparisons). The fluoride 
dentifrice/fluoride rinse regimen was associated with a statistically significantly higher EFU 
than both the fluoride dentifrice/no rinse regimen (P = .0010) and the placebo 
dentifrice/fluoride rinse treatment (P < .0001). There was no statistically significant difference 
in EFU between the fluoride dentifrice/no rinse and placebo dentifrice/fluoride rinse 
treatment groups. Analysis from the ANOVA model provided similar results (Table 2). 
3.2.3. Salivary fluoride (Table 3) 
The changes in salivary fluoride concentration between pre- and post-treatment samples on 
Day 1 were statistically significantly different (P < .0002) between all groups except between 
the fluoride dentifrice/fluoride rinse and placebo dentifrice/fluoride rinse groups. Analysis 
from the ANOVA model showed similar results. The changes in salivary fluoride 
concentration between Day 1 (pre-treatment) and Day 14 were statistically significantly 
different (P < .002) between either the fluoride dentifrice/with or without fluoride rinse groups 
and the placebo dentifrice/no rinse group only. Analysis from the ANOVA model did not 
show any significant differences. The changes in salivary fluoride concentration from Day 1 
(post-treatment) to Day 14 were statistically significantly different (P < .0002) between all 
treatment groups with the exception of between the fluoride dentifrice/fluoride rinse and 
placebo dentifrice/fluoride rinse groups. Analysis from the ANOVA model showed similar 
results. 
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3.2.4. Correlations 
Moderate positive correlations of the order of r=0.45 to r=0.51 (all P < .001) were observed 
between %SMHR and EFU in the three active-treatment groups, with a slightly negative (r = 
-0.27) but non-significant correlation in the placebo group. Salivary fluoride concentration 
correlated poorly with either %SMHR or EFU across all treatment groups, with statistical 
significance only shown for Day 14 salivary fluoride concentration and %SMHR in the 
fluoride dentifrice/no rinse group (r=-0.47; P = .0002) and EFU in the placebo dentifrice/no 
rinse group (r=0.31; P = .0285). 
3.3. Safety 
Treatment-emergent and treatment-related AEs are summarised in Table 4. There were 
three serious AEs: hematemesis in the fluoride dentifrice/fluoride rinse group, asthma in the 
placebo dentifrice/fluoride rinse group, and hypertension in the placebo dentifrice/no rinse 
group. None were related to study treatment; two (hematemesis and asthma) resulted in 
study withdrawal. All AEs subsequently resolved. 
 
4. Discussion 
The present in situ study was designed to investigate potential additive effects of an adjunct 
fluoride therapy and to explore the potential anti-caries benefits a fluoride mouthrinse can 
provide in its own right. The chosen in situ caries model has been extensively used to 
successfully study the effects of a range of fluoride delivery vehicles [10,12,21]. The study 
employed surface softened lesions covered in gauze to provide insight into the potential 
efficacy of anticaries agents during the early stages of caries by reproducing the conditions 
found in interproximal areas [10]. In this design, there was no abrasion component during 
the in situ phase as specimens were wrapped in gauze, thereby protecting the enamel 
surface from abrasive forces in the oral cavity. In such a design, it is anticipated that surface 
loss is an insignificant variable. While not confirmed in this study, a previous in vitro study 
employing more severe caries lesions demonstrated that no surface loss occurred [25].    
The present study demonstrated that a 220 ppm fluoride mouthrinse has predicted anti-
caries efficacy and that it should provide additive benefits to a conventional fluoride 
dentifrice even if used only once a day. In general, these results support those from other 
studies that demonstrate a fluoride mouthrinse can be a useful adjunct to a fluoride dentifrice 
[7]. The additional remineralisation achieved with the fluoride mouthrinse, as shown by 
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%SMHR, was directional to that of the fluoride dentifrice, which in itself is a potentially 
clinically important anti-caries benefit. However, the response effect between the three 
active (fluoride) treatment groups was small which may indicate that the level of cariogenic 
challenge in subjects participating in this study was not sufficient to demonstrate an 
additional benefit for the fluoride mouthrinse. In this model, subjects with modifiable partial 
dentures were employed, and, while it is considered that this study population is 
representative of adults, it is possible that the oral ecology of such subjects is subtly different 
compared to fully dentate individuals, resulting in less demineralisation following a 
cariogenic challenge and an under estimation of treatment effects for adjunctive treatments. 
Further studies on larger, more advanced lesions, and/or under more demineralising 
conditions, are warranted to elucidate the potential adjunctive benefit of fluoride 
mouthrinses.  
The fluoride mouthrinse (220 ppm fluoride) was used once daily in this study, which for 
fluoride mouthrinses above 90 ppm fluoride is according to its indication in the USA [26]. It 
was used only after night-time brushing as fluoride exposure at night has been shown to be 
more effective than rinsing in the morning [27] due to fluoride’s greater ability to enhance 
remineralisation than prevent demineralisation and its greater substantivity due to decreased 
salivary flow at night [28,29]. Comparative studies (e.g. day versus night, once versus twice 
daily usage, intermittent usage, and comparison between fluoride concentrations) are 
warranted to provide better clinical recommendations. Nonetheless, the present study has 
provided further evidence for the beneficial use of fluoride mouthrinses in caries prevention. 
The EFU data showed greater sensitivity and ability to discern between treatments than the 
%SMHR data. This is in agreement with previous studies employing this model [16,21,30] 
and can be explained by the greater capacity of the lesions to retain fluoride than their ability 
to be remineralised. Furthermore, and by virtue of the microbiopsy technique, the fluoride 
analysis captures surface and subsurface-bound fluoride, fluoride that may potentially be of 
relevance during a more severe cariogenic attack. 
A limitation of this study is that although the identity of the dentifrices was masked, 
participants could not be blinded as to whether or not they were using the fluoride 
mouthrinse; hence, observed differences may be due to this lack of blinding.   
In summary, this in situ caries study has shown that a 220 ppm fluoride rinse provides 
similar anti-caries benefits to that of an 1150 ppm fluoride dentifrice. The combined regimen 
of rinse and dentifrice provided further directional, although non-significant, benefits in terms 
of lesion remineralisation; however, statistically significant enhancements were observed in 
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lesion fluoride uptake. A relatively high number of adverse events were observed in this 
study; however, the number of adverse events across treatment groups was similar.  
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Figure legends 
Figure 1. Flow diagram of participant disposition 
ITT, intent to treat; PP, per protocol 
 
Figure 2. Effect of dentifrice and mouthrinse regimen on (left axis) SMH recovery and 
(right axis) EFU (per-protocol population) 
 
Data plotted are adjusted means and standard errors of the mean. Adjusted means and 95% 
confidence intervals from the ANOVA model are shown above the figures. 
EFU, enamel fluoride uptake; SMH, surface microhardness  
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Table 1. Between-treatment comparison of %SMHR (per-protocol population). 
Treatment comparison  
Between-treatment  
differencea (95% CI) P-valuea 
Wilcoxon 
P-valueb 
Fluoride dentifrice/fluoride rinse vs Fluoride dentifrice/no rinse 2.07 (-3.64, 7.78) 0.4752 0.0868 
Placebo dentifrice/fluoride rinse 4.79 (-0.99, 10.57) 0.1035 0.0906 
Placebo dentifrice/no rinse 21.55 (15.78, 27.32) <.0001 <.0001 
Fluoride dentifrice/no rinse vs Placebo dentifrice/fluoride rinse 2.72 (-2.92, 8.37) 0.3420 0.1713 
Placebo dentifrice/no rinse 19.48 (13.81, 25.15) <.0001 <.0001 
Placebo dentifrice/fluoride rinse vs Placebo dentifrice/no rinse 16.76 (11.06, 22.45) <.0001 <.0001 
aFrom ANOVA: Difference is first-named treatment minus second-named treatment such that a positive difference implies a larger response value for the first-
named treatment 
bp-value from Wilcoxon Signed-Rank Test 
%SMHR, percent surface microhardness recovery 
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Table 2. Between-treatment comparison of EFU (per-protocol population). 
Treatment comparison  
Between-treatment  
differencea (95% CI) P-valuea 
Wilcoxon 
P-valueb 
Fluoride dentifrice/fluoride rinse vs Fluoride dentifrice/no rinse 1.88 (0.75, 3.01) 0.0013 0.0010 
Placebo dentifrice/fluoride rinse 2.48 (1.34, 3.62) <.0001 <.0001 
Placebo dentifrice/no rinse 8.35 (7.21, 9.49) <.0001 <.0001 
Fluoride dentifrice/no rinse vs Placebo dentifrice/fluoride rinse 0.61 (-0.51, 1.72) 0.2862 0.5326 
Placebo dentifrice/no rinse 6.47 (5.35, 7.60) <.0001 <.0001 
Placebo dentifrice/fluoride rinse vs Placebo dentifrice/no rinse 5.87 (4.74, 7.00) <.0001 <.0001 
aFrom ANOVA: Difference is first-named treatment minus second-named treatment such that a positive difference implies a larger response value for the first-
named treatment 
bp-value from Wilcoxon Signed-Rank Test 
EFU, enamel fluoride uptake 
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Table 3. Between-treatment comparison of fluoride in saliva samples (per-protocol population). 
  Day 1 pre- to Day 1 post-treatment Day 1 pre-treatment to Day 14 Day 1 post-treatment to Day 14  
Treatment comparison Diffa (95% CI) 
P-
valuea 
Wilcoxon 
P-valueb Diffa (95% CI) 
P-
valuea 
Wilcoxon 
P-valueb Diffa (95% CI) 
P-
valuea 
Wilcoxon 
P-valueb 
F dent/f rinse vs F dent/no rinse 5.2 (2.64, 7.67) <.0001 <.0001 0.1 (-0.03, 0.15) 0.1605 0.1386 5.1 (2.66, 7.44) <.0001 <.0001 
Plac dent/F rinse 0.9 (-1.67, 3.4) 0.5016 0.4395 -0.0 (-0.09, 0.09) 0.9846 0.0665 0.9 (-1.56, 3.28) 0.4820 0.4395 
Plac dent/no rinse 13.8 (11.28, 16.36) <.0001 <.0001 0.7 (-0.02, 0.16) 0.1190 0.0001 13.3 (10.85, 15.72) <.0001 <.0001 
F dent/no rinse vs Plac dent/F rinse -4.3 (-6.78, -1.81) 0.0008 0.0001 -0.1 (-0.15, 0.02) 0.1524 0.5645 -4.2 (-6.55, -1.82) 0.0006 0.0001 
Plac dent/no rinse 8.7 (6.16, 11.16) <.0001 <.0001 0.0 (-0.08, 0.09) 0.8562 0.0017 8.2 (5.85, 10.63) <.0001 <.0001 
Plac dent/F rinse vs Plac dent/no rinse 12.9 (10.45, 15.46) <.0001 <.0001 0.1 (-0.02, 0.16) 0.1125 0.0559 12.4 (10.02, 14.82) <.0001 <.0001 
aBetween-treatment difference from ANOVA: Difference is first-named treatment minus second-named treatment such that a positive difference implies a 
larger response value for the first-named treatment 
bp-value from Wilcoxon Signed-Rank Test 
F, fluoride; dent, dentifrice; Plac, placebo  
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Table 4. Treatment-emergent adverse events (safety population). 
 
Fluoride dentifrice/ 
Fluoride rinse 
(n=57) 
Fluoride dentifrice/ 
No rinse 
(n=59) 
Placebo dentifrice/ 
Fluoride rinse 
(n=60) 
Placebo dentifrice/ 
No rinse 
(n=56) 
 n (%) nAE n (%) nAE n (%) nAE n (%) nAE 
Participants with ≥1 AE 17 (29.8) 20 18 (30.5) 22 15 (25.0) 22 13 (23.2) 26 
Participants with ≥1 oral AE 10 (17.5) 12 10 (16.9) 12 9 (15.0) 12 9 (16.1) 14 
Participants with ≥1 TRAE 3 (5.3) 4 1 (1.7) 1 2 (3.3) 4 6 (10.7) 8 
Treatment-related AEs         
 Dry mouth 1 (1.8) 1 0 0 0 0 0 0 
 Glossodynia 1 (1.8) 1 1 (1.7) 1 0 0 2 (3.6) 2 
 Lip dry 1 (1.8) 1 0 0 0 0 3 (5.4) 3 
 Parasthesia oral 1 (1.8) 1 0 0 1 (1.7) 1 1 (1.8) 1 
 Cheilitis 0 0 0 0 1 (1.7) 1 1 (1.8) 1 
 Oral discomfort 0 0 0 0 1 (1.7) 1 0 0 
 Throat tightness 0 0 0 0 1 (1.7) 1 0 0 
 Gingival ulceration 0 0 0 0 0 0 1 (1.8) 1 
AE, adverse event; TRAE, treatment-related AE; n (%), number (percent) of participants in treatment group; nAE, number of AEs. 
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